胆囊癌综合治疗的临床研究

doi:10.16139/j.1007-9610.2023.02.16

摘要/Abstract

摘要：

胆囊癌早期发现困难，进展到晚期而预后不佳。尽管根治性手术治疗是目前治愈胆囊癌的主要方法，但临床仅有少部分病人可获得根治性治疗。化疗、放疗、靶向治疗以及免疫治疗可能提高部分胆囊癌病人生存，然而如何治愈胆囊癌，仍是临床难点。本文对胆囊癌手术治疗、化疗、放疗、靶向治疗、免疫治疗等近年国内外临床研究进行文献复习。

关键词: 胆囊癌, 手术治疗, 化疗, 放疗, 靶向治疗

Abstract:

Early detection of gallbladder cancer is difficult with poor prognosis in late stage. Although radical surgical treatment is the main method to cure gallbladder cancer at present, only less patients have radical surgery clinically. Chemotherapy, radiotherapy, targeted therapy and immunotherapy may improve the survival of some patients with gallbladder cancer. However, how to cure gallbladder cancer is still difficult clinic. In this paper, the review of literatures at home and abroad on surgical treatment, chemotherapy, radiotherapy, targeted therapy, and immunotherapy for gallbladder cancer was done.

Key words: Gallbladder cancer, Surgical treatment, Chemotherapy, Radiation therapy, Targeted therapy

中图分类号:

R735.8

王远江, 邹浩. 胆囊癌综合治疗的临床研究[J]. 外科理论与实践, 2023, 28(02): 171-176.

WANG Yuanjiang, ZOU Hao. Clinical study on comprehensive treatment of gallbladder cancer[J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 171-176.

参考文献 51

[25]	陈亚进, 徐鋆耀. 腹腔镜技术在胆囊癌根治术中的应用评价[J]. 中国实用外科杂志, 2016, 36(10):1040-1044. doi: 10.7504/CJPS.ISSN1005-2208.2016.10.06
	CHEN Y J, XU Y Y. Laparoscopic approach for the management of gallbladder cancer[J]. Chin J Pract Surg, 2016, 36(10):1040-1044.
[26]	张亦弛, 王许安, 刘颖斌. 放射治疗在胆囊癌综合治疗中的应用进展[J]. 肝胆胰外科杂志, 2017, 29(5):430-432,436.
	ZHANG Y C, WANG X A, LIU Y B. Application progress of radiotherapy in the treatment of gallbladder carcinoma[J]. J Hepatopancreatobiliary Surg, 2017, 29(5):430-432,436.
[27]	杨倞, 冯飞灵, 周海华, 等. 胆囊癌术后辅助性放疗的疗效分析[J]. 中华肿瘤杂志, 2013, 35(7):534-539.
	YANG L, FENG F L, ZHOU H H, et al. Analysis of the efficacy of postoperative radiotherapy in gallbladder cancer[J]. Chin J Oncol, 2013, 35(7):534-539.
[28]	王玉栋, 王龙, 刘巍. 晚期胆道系统肿瘤内科治疗进展[J]. 中国肿瘤临床, 2012, 39(21):1678-1683.
	WANG Y D, WANG L, LIU W. Advances in medical treatment of advanced biliary system tumors[J]. Chin J Clin Oncol, 2021, 39(21):1678-1683.
[29]	WANG S J, LEMIEUX A, KALPATHY-CRAMER J, et al. Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer[J]. J Clin Oncol, 2011, 29(35):4627-4632. doi: 10.1200/JCO.2010.33.8020 pmid: 22067404
[30]	MA N, CHENG H, QIN B, et al. Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis[J]. BMC Cancer, 2015, 15:615. doi: 10.1186/s12885-015-1617-y pmid: 26337466
[31]	RANGARAJAN K, SIMMONS G, MANAS D, et al. Systemic adjuvant chemotherapy for cholangiocarcinoma surgery: a systematic review and meta-analysis[J]. Eur J Surg Oncol, 2020, 46(4 Pt A):684-693. doi: S0748-7983(19)31443-X pmid: 31761507
[32]	CHEN C, FENG W, ZHENG Y, et al. Intra-arterial chemotherapy improved survival of stage 2-3 gallbladder cancer after curative resection[J]. Onco Targets Ther, 2018, 11:2975-2979. doi: 10.2147/OTT URL
[33]	PRABHU R S, HWANG J. Adjuvant therapy in biliary tract and gall bladder carcinomas: a review[J]. J Gastrointest Oncol, 2017, 8(2):302-313. doi: 10.21037/jgo.2017.01.17 pmid: 28480069
[34]	VALLE J, WASAN H, PALMER D H, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14):1273-1281. doi: 10.1056/NEJMoa0908721 URL
[35]	单本杰, 胡冰. 吉西他滨联合替吉奥方案治疗晚期胆囊癌临床观察[J]. 肝胆外科杂志, 2015, 23(5):336-338.
	SHAN B J, HU B. Clinical observation of gemcitabine combined with tegafur in the treatment of advanced gall bladder cancer[J]. J Hepatobiliary Surg, 2015, 23(5):336-338.
[36]	周勇. ErbB信号通路及其对胆囊癌靶向治疗的研究进展[J]. 中国肿瘤生物治疗杂志, 2017, 24(4):447-452.
	ZHOU Y. ErbB signaling pathway and its targeted therapy in gallbladder cancer[J]. Chin J Cancer Biotherapy, 2017, 24(4):447-452.
[37]	SALAMA A K S, LI S, MACRAE E R, et al. Dabrafenib and trametinib in patients with tumors with BRAF(V600E) mutations: results of the NCI-MATCH trial subprotocol H[J]. J Clin Oncol, 2020, 38(33):3895-3904. doi: 10.1200/JCO.20.00762 URL
[38]	DOEBELE R C, DRILON A, PAZ-ARES L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials[J]. Lancet Oncol, 2020, 21(2):271-282. doi: S1470-2045(19)30691-6 pmid: 31838007
[39]	HARDING J, CLEARY J, SHAPIRO G, et al. Treating HER2-mutant advanced biliary tract cancer with neratinib: be-nefits of HER2-directed targeted therapy in the phase 2 SUMMIT “basket” trial[J]. Ann Oncol, 2019, 30:Suppl 4.
[40]	ANAGNOSTOU V, SMITH K N, FORDE P M, et al. Evolution of neoantigen landscape during immune checkpoint bloc-kade in non-small cell lung cancer[J]. Cancer Discov, 2017, 7(3):264-276. doi: 10.1158/2159-8290.CD-16-0828 URL
[41]	MCGRANAHAN N, FURNESS A J, ROSENTHAL R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade[J]. Science, 2016, 351(6280):1463-1469. doi: 10.1126/science.aaf1490 pmid: 26940869
[42]	KIESSLICH T, MAYR C, WACHTER J, et al. Activated hedgehog pathway is a potential target for pharmacological intervention in biliary tract cancer[J]. Mol Cell Biochem, 2014, 396(1-2):257-268. doi: 10.1007/s11010-014-2161-9 pmid: 25064451
[43]	ZONG H, YIN B, ZHOU H, et al. Inhibition of mTOR pathway attenuates migration and invasion of gallbladder cancer via EMT inhibition[J]. Mol Biol Rep, 2014, 41(7):4507-4512. doi: 10.1007/s11033-014-3321-4 URL
[44]	KIM R D, CHUNG V, ALESE O B, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer[J]. JAMA Oncol, 2020, 6(6):888-894. doi: 10.1001/jamaoncol.2020.0930 pmid: 32352498
[45]	MARABELLE A, FAKIH M, LOPEZ J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study[J]. Lancet Oncol, 2020, 21(10):1353-1365. doi: S1470-2045(20)30445-9 pmid: 32919526
[46]	MARABELLE A, LE D T, ASCIERTO P A, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase Ⅱ KEYNOTE-158 study[J]. J Clin Oncol, 2020, 38(1):1-10.
[47]	UENO M, IKEDA M, MORIZANE C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study[J]. Lancet Gastroenterol Hepatol, 2019, 4(8):611-621. doi: 10.1016/S2468-1253(19)30086-X URL
[48]	SUN D, MA J, WANG J, et al. Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer[J]. Cancer Immunol Immunother, 2019, 68(9):1527-1535. doi: 10.1007/s00262-019-02386-w pmid: 31535160
[49]	BRAHMER J R, TYKODI S S, CHOW L Q, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. N Engl J Med, 2012, 366(26):2455-2465. doi: 10.1056/NEJMoa1200694 URL
[50]	KAWAMOTO M, WADA Y, KOYA N, et al. Long-term survival of a patient with recurrent gallbladder carcinoma, treated with chemotherapy, immunotherapy, and surgery: a case report[J]. Surg Case Rep, 2018, 4(1):115. doi: 10.1186/s40792-018-0512-6 pmid: 30219954
[1]	RAWLA P, SUNKARA T, THANDRA K C, et al. Epidemiology of gallbladder cancer[J]. Clin Exp Hepatol, 2019, 5(2):93-102. doi: 10.5114/ceh.2019.85166 URL
[2]	LEE H, KWON W, HAN Y, et al. Optimal extent of surgery for early gallbladder cancer with regard to long-term survival: a meta-analysis[J]. J Hepatobiliary Pancreat Sci, 2018, 25(2):131-141. doi: 10.1002/jhbp.521 URL
[3]	SHUKLA S K, SINGH G, SHAHI K S, et al. Staging, treatment, and future approaches of gallbladder carcinoma[J]. J Gastrointest Cancer, 2018, 49(1):9-15. doi: 10.1007/s12029-017-0036-5 pmid: 29234972
[4]	方驰华, 张鹏, 陈康. 数字智能化诊断与治疗技术在胆道恶性肿瘤中的应用[J]. 中华消化外科杂志, 2019, 18(2):111-116.
	FANG C H, ZHANG P, CHEN K. The application of digital medical intelligent diagnosis and treatment techno-logy for biliary malignant tumors[J]. Chin J Dig Surg, 2019, 18(2):111-116.
[5]	KANTHAN R, SENGER J L, AHMED S, et al. Gallbladder cancer in the 21st century[J]. J Oncol, 2015, 2015:967472.
[6]	段安琪, 邱应和, 易滨, 等. 意外胆囊癌在腹腔镜切除术中或术后的处理对策[J]. 临床和实验医学杂志, 2016, 15(1):62-64.
	DUAN A Q, QIU Y H, YI B, et al. Approach of un-expected gallbladder cancer in laparoscopic surgery or after operation[J]. J Clin Exp Med, 2016, 15(1):62-64.
[7]	刘鹏, 张贤彬, 耿智敏, 等. 不同手术方式治疗T1b期胆囊癌效果的多中心研究[J]. 中华外科杂志, 2018, 56(5):355-359.
	LIU P, ZHANG X B, GENG Z M, et al. A multicenter retrospective study for the prognosis of T1b stage gallbladder carcinoma underwent different surgical procedure[J]. Chin J Surg, 2018, 56(5):355-359.
[8]	李斌, 刘辰, 姜小清. 胆囊癌规范化诊治专家共识(2016)[J]. 临床肝胆病杂志, 2017, 33(4):611-620.
	LI B, LIU C, JIANG X Q. Guideline for the diagnosis and therapy of gallbladder carcinoma(2016)[J]. J Clin Hepatology, 2017, 33(4):611-620.
[9]	LEE W, JEONG C Y, JANG J Y, et al. Do hepatic-sided tumors require more extensive resection than peritoneal-sided tumors in patients with T2 gallbladder cancer? Results of a retrospective multicenter study[J]. Surgery, 2017, 162(3):515-524. doi: 10.1016/j.surg.2017.05.004 URL
[10]	程南生. 胆囊癌外科治疗的共识与分歧[J]. 中国普外基础与临床杂志, 2019, 26(3):261-264.
	CHENG N S. Consensus and disagreement on surgical treatment of gallbladder cancer[J]. Chin J Bases Clin Gen Surg, 2019, 26(3):261-264.
[11]	滕达, 刘鹏, 耿智敏, 等. T1、T2期胆囊癌手术方式选择[J]. 中华肝脏外科手术学电子杂志, 2021, 10(1):24-28.
	TENG D, LIU P, GENG Z M, et al. Selection of surgical methods for T1 and T2 gallbladder carcinoma[J]. Chin J Hepat Surg(Electronic Edition), 2021, 10(1):24-28.
[12]	KWON W, KIM H, HAN Y, et al. Role of tumour location and surgical extent on prognosis in T2 gallbladder cancer: an international multicentre study[J]. Br J Surg, 2020, 107(10):1334-1343. doi: 10.1002/bjs.11618 URL
[13]	中华医学会外科学分会胆道外科学组, 中国医师协会外科医师分会胆道外科专业委员会. 胆囊癌诊断和治疗指南(2019版)[J]. 中华外科杂志, 2020, 58(4):243-251.
	Branch of Biliary Surgery, Chinese Surgical Society, Chinese Committee of Biliary Surgeons. Guideline for the diagnosis and treatment of gallbladder carcinoma (2019 edition)[J]. Chin J Surg, 2020, 58(4):243-251.
[14]	杜俊杰, 蓝伟锋, 黄兴华, 等. 胆囊癌的诊治进展[J]. 国际外科学杂志, 2020, 47(6):421-425.
	DU J J, LAN W F, HUANG X H, et al. Diagnosis and treatment of gallbladder cancer[J]. Int J Surg, 2020, 47(6):421-425.
[15]	MIZUNO T, EBATA T, YOKOYAMA Y, et al. Major hepatectomy with or without pancreatoduodenectomy for advanced gallbladder cancer[J]. Br J Surg, 2019, 106(5):626-635. doi: 10.1002/bjs.11088 pmid: 30762874
[16]	刘辰, 姜小清. 胆囊癌的综合治疗[J]. 肝胆外科杂志, 2018, 26(6):405-407.
	LIU C, JIANG X Q. Comprehensive treatment of gallbladder cancer[J]. J Hepatobiliary Surg, 2018, 26(6):405-407.
[17]	KIM H S, PARK J W, KIM H, et al. Optimal surgical treatment in patients with T1b gallbladder cancer: an international multicenter study[J]. J Hepatobiliary Pancreat Sci, 2018, 25(12):533-543. doi: 10.1002/jhbp.2018.25.issue-12 URL
[18]	ABRAMSON M A, PANDHARIPANDE P, RUAN D, et al. Radical resection for T1b gallbladder cancer: a decision analysis[J]. HPB (Oxford), 2009, 11(8):656-63. doi: 10.1111/j.1477-2574.2009.00108.x URL
[19]	ETHUN C G, POSTLEWAIT L M, LE N, et al. Association of optimal time interval to re-resection for incidental gallbladder cancer with overall survival: a multi-institution analysis from the US extrahepatic biliary malignancy consortium[J]. JAMA Surg, 2017, 152(2):143-149. doi: 10.1001/jamasurg.2016.3642 pmid: 27784058
[20]	FUKS D, REGIMBEAU J M, PESSAUX P, et al. Is port-site resection necessary in the surgical management of gallbladder cancer?[J]. J Visc Surg, 2013, 150(4):277-284. doi: 10.1016/j.jviscsurg.2013.03.006 pmid: 23665059
[21]	MIYAZAKI M, OHTSUKA M, MIYAKAWA S, et al. Classification of biliary tract cancers established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3rd English edition[J]. J Hepatobiliary Pancreat Sci, 2015, 22(3):181-196. doi: 10.1002/jhbp.v22.3 URL
[22]	ALOIA T A, JÁRUFE N, JAVLE M, et al. Gallbladder cancer: expert consensus statement[J]. HPB(Oxford), 2015, 17(8):681-690.
[23]	WIDMANN B, WARSCHKOW R, BEUTNER U, et al. Effect of lymphadenectomy in curative gallbladder cancer treatment: a systematic review and meta-analysis[J]. Langenbecks Arch Surg, 2020, 405(5):573-584. doi: 10.1007/s00423-020-01878-z
[24]	别平, 陈志宇. 胆囊癌诊治的困惑及未来突破方向[J]. 中国实用外科杂志, 2016, 36(10):1021-1024. doi: 10.7504/CJPS.ISSN1005-2208.2016.10.01
	BIE P, CHEN Z Y. Confusion in the diagnosis and treatment of gallbladder cancer and its future breakthrough[J]. Chin J Pract Surg, 2016, 36(10):1021-1024.
[51]	KOBAYASHI M, SAKABE T, ABE H, et al. Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer[J]. J Gastrointest Surg, 2013, 17(9):1609-1617. doi: 10.1007/s11605-013-2286-2 pmid: 23877328